BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) to Release Early Efficacy Data from Combination Study at AACR Annual Meeting
BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Combination study pairing KEYTRUDA with Bria-IMT is ongoing, with initial efficacy data for the first six patients to be released at AACR Annual Meeting BriaCell has closed the first tranche of a previously announced non-brokered private placement, … Continue reading “BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) to Release Early Efficacy Data from Combination Study at AACR Annual Meeting”